Abstract
“For many years generic companies were the poor relations of the
pharmaceutical industry, with modest growth rates and little or no
transnational business operations. As generics companies have grown, often by
acquisition, they have generally developed as international businesses.”
There has been a remarkable transformation in the pharmaceutical market, with
revenue growth in the generics business turning into a high growth segment. In
2006, global sales of generic pharmaceuticals were $ 77 billion.
The leading two generics companies have both generated sufficient revenues to
be described as major pharmaceutical companies. However there are also key
issues that impact the growth prospects of the generics companies, such as
fewer new therapeutic entities reaching the market- which ultimately reduces
the number of opportunities to launch new generic products. Another crucial
issue for the generics market is more biological agents. The introduction of
biosimilars has several legislative and regulatory constraints for generics
companies.
In response to some of these challenges, many leading generic companies have
pursued consolidation via mergers and acquisitions, increasing their market
muscle and improving their geographical reach. This has made the generics
market see a rush of takeovers.
Consolidation in the Generic Pharmaceutical Industry: An evolving landscape
closely examines the significant acquisitions in the industry and
forecasts which companies are shifting from single country marketing
strategies through mergers and take-overs.
Key Features of the Report:
- Solid overview of the generics market
- Tells the story behind the most competitive acquisitions- and why generics
companies are moving to lower cost manufacturing environments,
- Assesses the upcoming players in the generics market- Brazil, Mexico,
India, China and South Korea
- Identifies low penetration markets for short term revenue growth
- Profiles 11 generics companies
- Points out when the generics market will see slow growth, and why..
Companies mentioned in the report include:
- Abbott
- Actavi
- Allergan
- Apotex
- Aspen Pharmacare
- AstraZeneca
- Baxter
- Bristol-Myers
- Caraco.
- Chisie
- Cinfa
- Dr Reddy' s
- Egis
- Gedeon Richter
- GlaxoSmithKline
- Glenmark
- Greenstone (Pfizer)
- Hikma
- Hospira
- Krka
- Kyowa
- Mallinckrodt
- Merck
- Mylan
- Nichiiko
- Nicholas Piramal
- Novo Nordisk
- Par
- Perigo
- Pliva
- Ranbaxy
- Ratiopharm
- Richter
- Sandoz (Novartis)
- Sawai
- Sanofi-Aventis
- Stada
- Teva
- Torrent
- Towa
- Wockhardt
- Zambon
- Zentiva
- Zydus Cadila
| 
View Cart
